Antiretroviral therapy with efavirenz in HIV-positive pregnant women has been reported to increase the risk of neurological conditions in offspring.
State media has reported that the number of people living with HIV/AIDS has increased by 14% year-on-year.
A recent study carried out by researchers from the University of Zurich and University Hospital Zurich has discovered that the production of broad acting antibodies is dependent on the genome of the virus.
Financial modelling has been used to estimate the costs and likelihood of candidate medicines, vaccines, diagnostics and technologies launching, revealing gaps in the pipeline and in funding.
ViiV Healthcare has announced positive 48-week results from its Phase III ATLAS study of a long-acting, injectable, two-drug regimen for treating HIV.
ViiV healthcare has announced results of a 100-week Phase lll program and demonstrated the success of the first two-drug regimen, Juluca®.
Experimental HIV-1 vaccine regimen is safe and elicits a robust immune response according to results of a Phase I/IIa clinical trial.
In top-line results from a Phase IIa study, Abivax has reported mixed data, although ABX464 did appear to reduce HIV DNA in blood and rectal samples at a higher dose.
Research presented at ASM Microbe has revealed that Treg cells may be protecting babies from contracting HIV from their mothers in utero.
The US FDA and the European Medicines Agency are investigating reports of neural tube defects in babies born to women on GlaxoSmithKline’s antiretroviral drug dolutegravir.
